Anna Lee

Anna Lee asked about Kymera's approach to patient compliance in the KT-621 Phase IIb trials and how the durability of KT-621's effect relates to compliance.

Answer

CEO Nello Mainolfi addressed patient compliance in KT-621 Phase IIb trials, stating that Kymera employs robust measures to ensure adherence. He emphasized that protein degraders like KT-621 offer a unique advantage, as missing a single dose does not result in an immediate loss of pathway degradation, providing an additional layer of protection against adherence challenges.

Anna Lee asked about Kymera's approach to compliance in the KT-621 Phase 2b trials and how the durability of KT-621 ties into patient adherence.

Answer

Nello Mainolfi, Founder, President, and CEO, acknowledged the critical importance of adherence. He noted that while injectable biologics often involve on-site administration, oral drugs offer patients greater freedom. Kymera has implemented measures to ensure patient adherence in the trials. He highlighted that protein degraders, unlike small molecule inhibitors, maintain activity even if a dose is missed, providing an additional layer of protection against potential non-adherence.

Anna Lee from Truist inquired if recent FDA changes have impacted accelerated approval plans for PCNSL, asked for an update on business development efforts given the cash runway, and questioned broader oncology trends affecting Curis.

Answer

CDO Jonathan Zung stated that alignment with the FDA remains unchanged. CEO James Dentzer acknowledged industry-wide FDA uncertainty but felt confident due to PCNSL having no approved drugs. CFO Diantha Duvall confirmed the cash runway extends into 2026 and the company is actively evaluating financing opportunities.